Meetings: Disease, Disability, and Injury Prevention and Control Special Emphasis Panel, 41406 [05-14162]
Download as PDF
<![CDATA[
41406
Federal Register / Vol. 70, No. 137 / Tuesday, July 19, 2005 / Notices
d. Budget.
e. Measures of Effectiveness.
f. Additional Requested Information.
2. Financial status report, no more
than 90 days after the end of the budget
period.
3. Final financial and performance
reports, no more than 90 days after the
end of the project period.
These reports must be mailed to the
Grants Management or Contract
Specialist listed in the ‘‘Agency
Contacts’’ section of this announcement.
VII. Agency Contacts
We encourage inquiries concerning
this announcement.
For general questions, contact:
Technical Information Management
Section, CDC Procurement and Grants
Office, 2920 Brandywine Road, Atlanta,
GA 30341; Telephone: 770–488–2700.
For program technical assistance,
contact: Michael Brown, Project Officer,
Centers for Disease Control and
Prevention (CDC), National Center on
Birth Defects and Developmental
Disabilities, Division of Human
Development and Disability, 1600
Clifton Road NE., Mailstop E–88,
Atlanta, GA 30333; Telephone: 404–
498–3006; E-mail: MABrown@cdc.gov.
For financial, grants management, or
budget assistance, contact: Mildred
Garner, Grants Management Officer,
CDC Procurement and Grants Office,
2920 Brandywine Road, Atlanta, GA
30341; Telephone: (770) 488–2745; Email: mqg4@cdc.gov.
VIII. Other Information
This and other CDC funding
opportunity announcements can be
found on the CDC Web site, Internet
address: https://www.cdc.gov. Click on
‘‘Funding’’ then ‘‘Grants and
Cooperative Agreements.’’
Dated: July 13, 2005.
Alan A. Kotch,
Acting Director, Procurement and Grants
Office, Centers for Disease Control and
Prevention.
[FR Doc. 05–14166 Filed 7–18–05; 8:45 am]
Control and Prevention (CDC)
announces the following meeting:
Name: Disease, Disability, and Injury
Prevention and Control Special Emphasis
Panel (SEP): Intervention for Individuals
with Fetal Alcohol Syndrome: Transitioning
Science to Community Project, Request for
Application (RFA) #DD 05–079 and
Implementing Community-Level Strategies
for Fetal Alcohol Syndrome Prevention and
Surveillance in South Africa, RFA #DD 05–
118.
Times and Dates: 1 p.m.–5 p.m., August 3,
2005 (Closed).
Place: Teleconference.
Status: The meeting will be closed to the
public in accordance with provisions set
forth in Section 552b(c)(4) and (6), Title 5
U.S.C., and the Determination of the Director,
Management Analysis and Services Office,
CDC, pursuant to Public Law 92–463.
Matters To Be Discussed: The meeting will
include the review, discussion, and
evaluation of applications received in
response to: Intervention for Individuals with
Fetal Alcohol Syndrome: Transitioning
Science to Community Project, Request for
Application (RFA) #DD 05–079 and
Implementing Community-Level Strategies
for Fetal Alcohol Syndrome Prevention and
Surveillance in South Africa, RFA #DD 05–
118.
For Further Information Contact: Pamela J.
Wilkerson, MPA, Scientific Review
Administrator, 24 Executive Park Drive, NE.,
Mailstop E74, Atlanta, GA 30333, Telephone
(404) 498–2556.
The Director, Management Analysis and
Services Office, has been delegated the
authority to sign Federal Register notices
pertaining to announcements of meetings and
other committee management activities, for
both CDC and the Agency for Toxic
Substances and Disease Registry.
Dated: July 12, 2005.
Alvin Hall,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.
[FR Doc. 05–14162 Filed 7–18–05; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
BILLING CODE 4163–18–P
[Docket No. 2003D–0167] (formerly Docket
No. 03D–0167)
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Guidance for Industry on Dispute
Resolution Procedures for ScienceBased Decisions on Products
Regulated by the Center for Veterinary
Medicine; Availability
Centers for Disease Control and
Prevention
Food and Drug Administration,
Meetings: Disease, Disability, and
Injury Prevention and Control Special
Emphasis Panel
AGENCY:
In accordance with Section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), the Centers for Disease
The Food and Drug
Administration (FDA) is announcing the
availability of a guidance for industry
VerDate jul<14>2003
17:15 Jul 18, 2005
Jkt 205001
HHS.
ACTION:
Notice.
SUMMARY:
PO 00000
Frm 00038
Fmt 4703
Sfmt 4703
(#79) entitled ‘‘Guidance for Industry:
Dispute Resolution Procedures for
Science-Based Decisions on Products
Regulated by the Center for Veterinary
Medicine (CVM).’’ This guidance
document describes dispute resolution
procedures by which sponsors,
applicants, or manufacturers of FDAregulated products for animals may
request review of science-based
decisions. This guidance does not
address procedures for handling issues
associated with FDA’s new initiative to
enhance pharmaceutical good
manufacturing practices (GMPs).
DATES: Submit written or electronic
comments on agency guidances at any
time.
ADDRESSES: Submit written requests for
single copies of the guidance to the
Communications Staff (HFV–12), Center
for Veterinary Medicine, Food and Drug
Administration, 7519 Standish Pl.,
Rockville, MD 20855. Send one selfaddressed adhesive label to assist that
office in processing your requests.
Submit written comments on this
guidance to the Division of Dockets
Management (HFA–305), Food and Drug
Administration, 5630 Fishers Lane, rm.
1061, Rockville, MD 20852. Submit
electronic comments to https:///
www.fda.gov/dockets/ecomments.
Comments should be identified with the
full title of the guidance and the docket
number found in brackets in the
heading of this document. See the
SUPPLEMENTARY INFORMATION section for
electronic access to the guidance
document.
FOR FURTHER INFORMATION CONTACT:
Marcia Larkins, Center for Veterinary
Medicine (HFV–7), Food and Drug
Administration, 7519 Standish Pl.,
Rockville, MD 20855, 301–827–4535, email: mlarkins@cvm.fda.gov.
SUPPLEMENTARY INFORMATION:
I. Background
In the Federal Register of May 19,
2003 (68 FR 27094), FDA published a
notice of availability for a draft guidance
for industry entitled ‘‘Dispute
Resolution Procedures for ScienceBased Decisions on Products Regulated
by the Center for Veterinary Medicine
(CVM)’’ giving interested persons until
August 4, 2003, to submit comments on
the draft guidance and until July 18,
2003, to comment on the information
collection. FDA considered all
comments received and, where
appropriate, made changes in the
guidance.
II. Significance of Guidance
This level 1 guidance is being issued
consistent with FDA’s good guidance
E:\FR\FM\19JYN1.SGM
19JYN1
]]>Agencies
[Federal Register Volume 70, Number 137 (Tuesday, July 19, 2005)]
[Notices]
[Page 41406]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 05-14162]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Meetings: Disease, Disability, and Injury Prevention and Control
Special Emphasis Panel
In accordance with Section 10(a)(2) of the Federal Advisory
Committee Act (Pub. L. 92-463), the Centers for Disease Control and
Prevention (CDC) announces the following meeting:
Name: Disease, Disability, and Injury Prevention and Control
Special Emphasis Panel (SEP): Intervention for Individuals with
Fetal Alcohol Syndrome: Transitioning Science to Community Project,
Request for Application (RFA) DD 05-079 and Implementing
Community-Level Strategies for Fetal Alcohol Syndrome Prevention and
Surveillance in South Africa, RFA DD 05-118.
Times and Dates: 1 p.m.-5 p.m., August 3, 2005 (Closed).
Place: Teleconference.
Status: The meeting will be closed to the public in accordance
with provisions set forth in Section 552b(c)(4) and (6), Title 5
U.S.C., and the Determination of the Director, Management Analysis
and Services Office, CDC, pursuant to Public Law 92-463.
Matters To Be Discussed: The meeting will include the review,
discussion, and evaluation of applications received in response to:
Intervention for Individuals with Fetal Alcohol Syndrome:
Transitioning Science to Community Project, Request for Application
(RFA) DD 05-079 and Implementing Community-Level Strategies
for Fetal Alcohol Syndrome Prevention and Surveillance in South
Africa, RFA DD 05-118.
For Further Information Contact: Pamela J. Wilkerson, MPA,
Scientific Review Administrator, 24 Executive Park Drive, NE.,
Mailstop E74, Atlanta, GA 30333, Telephone (404) 498-2556.
The Director, Management Analysis and Services Office, has been
delegated the authority to sign Federal Register notices pertaining
to announcements of meetings and other committee management
activities, for both CDC and the Agency for Toxic Substances and
Disease Registry.
Dated: July 12, 2005.
Alvin Hall,
Director, Management Analysis and Services Office, Centers for Disease
Control and Prevention.
[FR Doc. 05-14162 Filed 7-18-05; 8:45 am]
BILLING CODE 4163-18-P
